cdactin,nivolumab,cabozantinib
miyarisan,bms,osel
['nivo', 'rcc,(-irccs),(-srcc),(-urcc)', 'cbm588']
very interesting data from on use of cbm588 with nivo+cabo. small trial, but a second randomized clinical trial with a different io-based regimen showing signals of efficacy in rcc
#asco23 
Oncologist, physician-scientist, Assistant Professor @YaleCancer @YaleMed | cancer immunotherapy, genomics, kidney cancer | tweets ≠ medical advice.